STOK (Stoke Therapeutics) Institutional Ownership: 119.24% (As of Jul. 08, 2026)


STOK Stoke Therapeutics Inc STOK
45 GF Score
Price $33.02
GF Value $10.13
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Stoke Therapeutics Institutional Ownership?

Stoke Therapeutics STOK +1.82% 45 Institutional Ownership is 119.24% as of Jul. 08, 2026. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $10.13 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Stoke Therapeutics's institutional ownership is 119.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Stoke Therapeutics's Insider Ownership is 0.88%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Stoke Therapeutics's Float Percentage Of Total Shares Outstanding is 96.14%.

Stoke Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Stoke Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stoke Therapeutics Institutional Ownership Chart

Stoke Therapeutics Historical Data

The historical data trend for Stoke Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 46.08 41.67 43.13 43.68 43.41 43.98 46.88 46.66 46.77 47.99
STOK
45GF Score
Stoke Therapeutics Inc STOK
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stoke Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 119.24% mean?
Stoke Therapeutics (STOK) has a Institutional Ownership of 119.24% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Stoke Therapeutics and its competitors.
Is Stoke Therapeutics' Institutional Ownership too high?
Stoke Therapeutics' current Institutional Ownership is 119.24%. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Institutional Ownership compare to VRDN and ZLAB?
Stoke Therapeutics' Institutional Ownership of 119.24% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current Institutional Ownership is 119.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.13, compared to a current price of $33.02 — trading 226% above its estimated fair value. The current Institutional Ownership is 119.24%. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Institutional Ownership is 119.24% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stoke Therapeutics (STOK) Overvalued in 2026?

Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued. The current stock price of $33.02 is trading 226% above its estimated GF Value™ of $10.13. GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.

Key valuation signals for STOK:

  • Institutional Ownership: 119.24%
  • GF Value™: $10.13 vs. price of $33.02 (226% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stoke Therapeutics Business Description

Other Exchanges 0GT:Germany
Address 45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score

Get the complete analysis for STOK

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.02
Price
$10.13
GF Value